Forte Biosciences to Host R&D Day December 3, 2024
Forte Biosciences, Inc. (FBRX)
Company Research
Source: Business Wire
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced it will host an R&D Day on December 3, 2024 at 4:30 p.m. ET.The R&D Day will focus on the development of FB102 across autoimmune indications and will feature key thought leaders in celiac disease, vitiligo and alopecia areata including Prof. Jason Tye-Din MD, PhD, Head of Celiac Research at the Walter and Eliza Hall Institute, Prof. Christopher Ma MD, MPH, FRCPC, academic gastroenterologist at the Cumming School of Medicine, University of Calgary and Prof. David Rosmarin, MD, Chair of the Department of Dermatology at the School of Medicine, Indiana University.Use the link below to register for the event:https://lifescievents.com/event/fortebiorx/About ForteForte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is a proprietary anti-CD122 m
Show less
Read more
Impact Snapshot
Event Time:
FBRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FBRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FBRX alerts
High impacting Forte Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
FBRX
News
- Forte Biosciences, Inc. (NASDAQ: FBRX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $64.00 price target on the stock.MarketBeat
- Forte Biosciences, Inc. Announces Oversubscribed $53 Million Private Placement From Leading Healthcare Institutional Investors to Advance FB102 Across Autoimmune IndicationsBusiness Wire
- Forte Biosciences, Inc. (NASDAQ: FBRX) had its price target raised by analysts at Chardan Capital from $3.00 to $64.00. They now have a "buy" rating on the stock.MarketBeat
- Forte Biosciences, Inc. Announces Third Quarter 2024 Results and Provides Business UpdateBusiness Wire
FBRX
Sec Filings
- 1/2/25 - Form 4
- 1/2/25 - Form 4
- 12/31/24 - Form DEF
- FBRX's page on the SEC website